Literature DB >> 28848015

Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection.

Marguerite L Monogue1, David P Nicolau2,3.   

Abstract

Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in the neutropenic murine complicated urinary tract infection (cUTI) model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translational value to human outcomes. Our data support the translational utility of this murine model to cUTI in humans as humanized exposures produced microbiologic outcomes consistent with the phenotypic profiles of the organisms.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ESBL; Escherichia coli; cefepime; ertapenem; levofloxacin; urinary tract infection

Mesh：

Substances：

Year:  2017        PMID： 28848015      PMCID： PMC5655047          DOI： 10.1128/AAC.01329-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms.

Authors:  H EAGLE; R FLEISCHMAN; A D MUSSELMAN
Journal:  Ann Intern Med       Date:  1950-09       Impact factor: 25.391

Review 2.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

3.  Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria.

Authors:  Jeffrey J Fong; Lucia Rosé; Elizabeth A Radigan
Journal:  Ann Pharmacother       Date:  2012-03-06       Impact factor: 3.154

4.  In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

5.  Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.

Authors:  C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

6.  Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.

Authors:  Jennifer A Huntington; George Sakoulas; Obiamiwe Umeh; Daniel J Cloutier; Judith N Steenbergen; Caleb Bliss; Ellie J C Goldstein
Journal:  J Antimicrob Chemother       Date:  2016-03-18       Impact factor: 5.790

7.  Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo-β-lactamase (VIM) in a murine thigh infection model.

Authors:  Islam M Ghazi; Jared L Crandon; Emil P Lesho; Patrick McGann; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

8.  Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Yu Bin Seo; Jacob Lee; Young Keun Kim; Seung Soon Lee; Jeong-A Lee; Hyo Youl Kim; Young Uh; Han-Sung Kim; Wonkeun Song
Journal:  BMC Infect Dis       Date:  2017-06-07       Impact factor: 3.090

9.  Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis.

Authors:  Jessina C McGregor; George P Allen; David T Bearden
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423
  9 in total
  3 in total

1.  Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.

Authors:  William J Weiss; Mark E Pulse; Phung Nguyen; Kelly Peterson; Jessica Silva; Jerry W Simecka; David Valtierra; Mojgan Sabet; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.

Authors:  Marguerite L Monogue; Sara Giovagnoli; Caterina Bissantz; Claudia Zampaloni; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Evaluation of Immunocompetent Urinary Tract Infected Balb/C Mouse Model For the Study of Antibiotic Resistance Development Using Escherichia Coli CFT073 Infection.

Authors:  Ashok Chockalingam; Sharron Stewart; Lin Xu; Adarsh Gandhi; Murali K Matta; Vikram Patel; Leonard Sacks; Rodney Rouse
Journal:  Antibiotics (Basel)       Date:  2019-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.